According to a research it has been discovered that Sharpin can be used in treatment of cancer and autoimmune disease. Sharpin is a protein that controls inflammation induced by TNF (Tumour Necrosis Factor), a part of body’s defence against cancer.

TNF protects the body against bacterial infection, viruses and other pathogens. When TNF runs out of control, it contributes to inflammation and autoimmune diseases, such as chronic proliferative dermatitis (CPDM). According to research the mice deficient in Sharpin develops CPDM.

The study was authored by Cancer Research UK funded scientists based at Imperial College London in collaboration with A/Professor John Silke (La Trobe) and Dr. Andrew Webb and A/Professor Tony Purcell (Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne).

Professor John Silk said that Sharpin could be completely resolved by switching off TNF. He said that TNF controls from autoimmune diseases such as rheumatoid arthritis and psoriasis - to cancer.

Meanwhile, Dr. Webb said that they are very excited from the discovery of new drug, which was earlier not possible because of technological barriers.

He revealed that they will now test TNF for the better understanding of its functions.